Preclinical Imaging

临床前成像

• 批准号: 8078034
• 负责人: RICHARD V MAZURCHUK
• 金额: $ 16.25万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8078034
• 关键词: Angiogenesis Inhibitors; Animal Disease Models; Animals; Area; Arts; Basic Science; Biotechnology; Blood Vessels; Boston; Budgets; Buffaloes; Cancer Center Support Grant; Cancer Detection; Chemicals; Clinical Research; Computer software; Custom; Data; Data Analyses; Data Set; Development; Diffusion; Discipline of Nuclear Medicine; Drug Delivery Systems; Drug Kinetics; Electronics; Faculty; Fostering; Functional Magnetic Resonance Imaging; Gadolinium DTPA; Goals; Hour; Housing; Human; Image; Image Analysis; Image Cytometry; Imagery; Imaging Techniques; Imaging technology; Knowledge; Label; Laboratories; Lanthanoid Series Elements; Life; Lysine; Magnetic Resonance; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Maps; Methodology; Methods; Molecular; Molecular Weight; Neoplasms in Vascular Tissue; Optics; Permeability; Pharmacologic Substance; Phenotype; Physiology; Protocols documentation; Recruitment Activity; Research; Research Personnel; Resolution; Resources; Screening procedure; Sensitivity and Specificity; Services; Spectrum Analysis; Stress Tests; System; Techniques; Therapeutic; Three-dimensional analysis; Time; Training; Transgenic Mice; Treatment Efficacy; Tumor Oxygenation; Universities; Validation; Visual; base; blood oxygen level dependent; cohort; cost; data acquisition; design; digital; fluorescence imaging; image processing; in vivo; instrumentation; interest; intravital microscopy; magnetic field; member; multimodality; new technology; novel; optical imaging; pharmacodynamic model; pre-clinical; programs; research study; response; tool; tumor

The goal of RPCI's Preclinical Imaging Resource (PIR) is to advance small animal imaging methodology at the molecular, cellular and biosystem level. This is accomplished by facilitating development of novel basic science and clinical research, promoting advances in biotechnology, fostering development of new Pharmaceuticals and assessing in vivo drug delivery and therapeutic efficacy. The PIR currently offers customized magnetic resonance (MR) protocols designed to answer specific questions related to: (i) cancer detection, (ii) tumor vascular function, (iii) therapeutic response, (iv) animal phenotyping and (v) pharmacokinetic /pharmacodynamic modeling. In addition, the Resource provides whole-body fluorescence imaging of live animals and facilitates collaborative microPET research in conjunction with the University at Buffalo (UB). The aim is to provide readily available access and training to noninvasive, state-of-the-art in vivo imaging technologies at an affordable cost to CCSG members. The PIR is available 24 hours/day, 7 days/week. Three general types of MR services are offered: (a) instrumentation and expertise to acquire high resolution (< 50 urn2 in-plane spatial and < 100 ms temporal) heteronuclear imaging and spectroscopy data, (b) expertise and software for quantitative image analysis and (c) visualization of 2D and 3D data sets for probing structural/functional relationships. MR instrumentation includes a 4.7 T wide bore (33 cm) magnet incorporating Bruker's Avance platform with ParaVision¿ 4.0 OS, shielded Accustar gradients and digital system electronics. The MR system represents the highest magnetic field strength scanner available within 200 miles of RPCI. Recently expanded services include whole body in vivo optical and multispectral fluorescence imaging. Intravital Microscopy (IVM) using a MR compatible window chamber is also available for fluorescence imaging with MR validation. Data acquisition, hardcopy, display, qualitative/quantitative analysis and 3D renderings of digitally acquired data sets are offered as chargeback services. The Resource is used by five programs and 99% of users are CCSG members. $65,218 in CCSG support is requested, representing 12% of the total operating budget.

RPCI的临床前成像资源（PIR）的目标是推进小动物成像 分子，细胞和生物系统水平的方法。这是通过支持开发来实现的 新型的基础科学和临床研究，促进生物技术的进步，促进 新药物和体内药物递送和治疗有效性的评估。 PIR目前提供 定制的磁共振（MR）方案旨在回答与以下方面有关的特定问题：（i）癌症 检测，（ii）肿瘤血管功能，（iii）治疗反应，（iv）动物表型和（v） 药代动力学 /药效学建模。此外，资源提供全身荧光 现场动物的成像并促进了与大学合作研究 布法罗（UB）。目的是为无创，最先进的访问和培训提供 CCSG成员的体内成像技术以负担得起的成本。 PIR可用24小时/天，7 天/周。 提供了三种一般类型的MR服务类型：（a）获得高的仪器和专业知识 分辨率（<50 URN2平面空间和<100 ms临时）异核成像和光谱数据， （b）用于定量图像分析的专业知识和软件，以及（c）可视化2D和3D数据集的 探测结构/功能关系。 MR仪器包括4.7吨宽的孔（33厘米）磁铁 将Bruker的Avance平台与Paravision融合了4.0 OS，屏蔽的焦点梯度和数字 系统电子。 MR系统代表可用的最高磁场强度扫描仪 RPCI 200英里。最近扩展的服务包括整个身体在体内光学和多光谱 荧光成像。还提供了使用MR兼容窗室的插入式显微镜（IVM） 用于MR验证的荧光成像。数据获取，硬拷贝，显示，定性/定量 以数字化数据集的分析和3D渲染作为退款服务。 该资源由五个程序使用，99％的用户是CCSG成员。 CCSG $ 65,218 请求支持，占总运营预算的12％。